D-20133

D-20133 is an orally active Hexadecylphosphocholine analog. D-20133 can both enhance and inhibit antigen-induced histamine release. D-20133 shows antineoplastic activity against small DMBA (HY-W011845) -induced mammary carcinomas[1][2].

Product Specifications

CAS Number

[146764-26-3]

UNSPSC

12352005

Target

Drug Derivative; Histamine Receptor

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Others

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Smiles

CCCCCCCCCCCCCCCCCCOP(OCC[N+]1(CCCCC1)C)([O-])=O

Molecular Formula

C26H54NO4P

Molecular Weight

475.69

References & Citations

[1]Grosman N. Effect of the anti-neoplastic agents edelfosine (ET-18-OCH3), ilmofosine (BM 41.440) and the hexadecylphosphocholine analogues D-20133 and D-21266 on histamine release from isolated rat mast cells. Immunopharmacology. 1999 Nov;44 (3) :211-21.|[2]Stekar J, et al. Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133. Cancer Chemother Pharmacol. 1993;32 (6) :437-44.